Overview

4D Molecular Therapeutics develops gene therapies to treat serious genetic diseases by delivering specific genetic material to patients' cells using adeno-associated virus (AAV) vectors. Their focus is on patients with conditions like cystic fibrosis, and they operate in the biopharmaceutical market, emphasizing research and clinical trials before commercialization. The company differentiates itself through its proprietary "Therapeutic Vector Evolution" technology and has recently secured significant funding to advance its therapies. The goal of 4DMT is to lead in the development of effective gene therapies for genetic disorders.

💡 Want to apply to 4D Molecular Therapeutics?

You have ways to get a 4D Molecular Therapeutics referral from your network.

Get referrals →

Simplify's Take

What believers are saying

• 4DMT secured a $962 million deal with Astellas Pharma for R100 vector technology.
• Positive Phase 1/2 AEROW trial data for 4D-710 shows promise in cystic fibrosis treatment.
• Lifting of clinical hold on 4D-310 suggests regulatory progress and pipeline advancement.

What critics are saying

• Potential competition from CRISPR Therapeutics and Editas Medicine in gene therapy.
• Reliance on partnerships like Astellas could pose risks if expectations aren't met.
• Stock price fluctuations from public offerings may impact financial stability.

What makes 4D Molecular Therapeutics unique

• 4DMT uses proprietary Therapeutic Vector Evolution for advanced AAV vector development.
• Their R100 vector technology effectively penetrates the internal limiting membrane in eye therapies.
• 4DMT focuses on aerosolized gene therapies, like 4D-710 for cystic fibrosis lung disease.

Help us improve and share your feedback! Did you find this helpful?

YesNo